Back

Selective reduction of left ventricular ejection time (LVET) in hypertrophic cardiomyopathy patients carrying mutations in MYBPC3

13 May 2024 (14:00 - 14:45)
Organised by: Logo
Congress Presentation Part of: Myocardial disease - clinical 7 Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Monica Patten

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

7 More presentations in this session

Presentation thumbnail
Identification of a novel actin gene mutation, ACTC1 p.Asn94Ile, in a family with cardiomyopathy and conduction disease
Doctor R. Sepp (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Refining the diagnosis of hypertrophic cardiomyopathy with a machine learning-based radiomics model: a cardiovascular magnetic resonance study
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video
Presentation thumbnail
Different exercise hemodynamic profiles in obstructive and nonobstructive hypertrophic cardiomyopathy: importance of unmasking diastolic dysfunction
Doctor C. Baratto (Bergamo, IT)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance feature tracking identifies preclinical abnormalities in hypertrophic cardiomyopathy sarcomere gene mutation carriers
Doctor F. Negri (Udine, IT)
Abstract Slides Video
Presentation thumbnail
Unraveling the complexity of hypertrophic cardiomyopathy: a machine learning-based radiomics model to predict phenotype and cardiovascular events
Doctor I. Miranda (Amadora, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Myocardial disease - clinical 7

The Event

Event poster

Heart Failure 2024

13 May 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Different variants, same gene: similar or different evolutionary behavior throughout life?
thumbnail
Congress Presentation
MYBPC3 genotypes associated with familial hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Interim results from MyCLIMB, a natural history study of pediatric MYBPC3-associated hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources